Pelareorep

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

Retrieved on: 
Wednesday, July 27, 2022

SAN DIEGO, CA and CALGARY, AB, July 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss a corporate update and financial results for the second quarter of 2022.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent.
  • Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements.
  • It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Retrieved on: 
Wednesday, May 4, 2022

SAN DIEGO and CALGARY, AB, May 4, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced new clinical biomarker data demonstrating pelareorep's immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+/HER2- breast cancer. The data, which are featured in a poster presentation at the 2022 European Society for Medical Oncology (ESMO) Breast Cancer Meeting, are from cohorts 1 and 2 of the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced new clinical biomarker data demonstrating pelareorep's immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+/HER2- breast cancer.
  • The data, which are featured in a poster presentation at the 2022 European Society for Medical Oncology (ESMO) Breast Cancer Meeting, are from cohorts 1 and 2 of the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • Cohorts 1 and 2 of AWARE-1 exclusively enrolled patients with HR+/HER2- disease, the breast cancer subtype that Oncolytics intends to examine in a future registrational study.
  • CelTIL score is a metric for tumor inflammation and cellularity and is associated with improved clinical outcomes in breast cancer patients.

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

Retrieved on: 
Monday, May 2, 2022

(NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting, which is taking place both online and in-person at hub27 Messe Berlin in Berlin, Germany from May 3-5, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting, which is taking place both online and in-person at hub27 Messe Berlin in Berlin, Germany from May 3-5, 2022.
  • The accepted abstract (#364) is available on the ESMO Breast Cancer Meeting website .
  • Evaluation of these cohorts was the primary focus of AWARE-1 as HR+/HER2- is the breast cancer subtype Oncolytics intends to investigate in a future registrational study.
  • They also support pelareorep's immune-based mechanism of action and suggest that the combination of pelareorep and atezolizumab may improve outcomes in breast cancer.

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

Retrieved on: 
Monday, May 2, 2022

(NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting, which is taking place both online and in-person at hub27 Messe Berlin in Berlin, Germany from May 3-5, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting, which is taking place both online and in-person at hub27 Messe Berlin in Berlin, Germany from May 3-5, 2022.
  • The accepted abstract (#364) is available on the ESMO Breast Cancer Meeting website .
  • Evaluation of these cohorts was the primary focus of AWARE-1 as HR+/HER2- is the breast cancer subtype Oncolytics intends to investigate in a future registrational study.
  • They also support pelareorep's immune-based mechanism of action and suggest that the combination of pelareorep and atezolizumab may improve outcomes in breast cancer.

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, April 28, 2022

SAN DIEGO and CALGARY, AB, April 28, 2022 /PRNewswire/ --Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, May 5, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the first quarter of 2022.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent.
  • Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements.
  • It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, April 28, 2022

SAN DIEGO and CALGARY, AB, April 28, 2022 /PRNewswire/ --Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, May 5, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the first quarter of 2022.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent.
  • Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements.
  • It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022

SAN DIEGO and CALGARY, AB , April 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.
  • These data also demonstrate a clinical response correlating with changes in T cell clonality and post-treatment increases in innate and adaptive immune cells within the TME.
  • Collectively, these results indicate that the sustained clinical benefits observed were driven by pelareorep's recruitment of anti-cancer immune cells into the TME.
  • A copy of the poster will also be posted to thePosters & Publicationspage of Oncolytics' website ( LINK ) following the conclusion of the meeting.

Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022

SAN DIEGO and CALGARY, AB, April 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.
  • These data also demonstrate a clinical response correlating with changes in T cell clonality and post-treatment increases in innate and adaptive immune cells within the TME.
  • Collectively, these results indicate that the sustained clinical benefits observed were driven by pelareorep's recruitment of anti-cancer immune cells into the TME.
  • A copy of the poster will also be posted to thePosters & Publicationspage of Oncolytics' website ( LINK ) following the conclusion of the meeting.

Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress

Retrieved on: 
Wednesday, April 6, 2022

(NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
  • Our 2021 year-end letter to shareholders detailed our accomplishments last year and set the stage for the catalysts we expect to see in 2022.
  • I am excited to update you on our progress this past quarter and highlight how it has driven the momentum behind our clinical and preclinical programs.
  • It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.

Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress

Retrieved on: 
Wednesday, April 6, 2022

(NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.
  • Our 2021 year-end letter to shareholders detailed our accomplishments last year and set the stage for the catalysts we expect to see in 2022.
  • I am excited to update you on our progress this past quarter and highlight how it has driven the momentum behind our clinical and preclinical programs.
  • It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time.